DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma in Relapse

Interventions: Drug: Panobinostat
Drug: Dexamethasone
Drug: Lenalidomide
Drug: Bortezomib

First Posted Date: 2013-10-18

Last Posted Date: 2021-09-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT01965353

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

RPFNA Assessment of Exercise Effect in Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Exercise Intervention

First Posted Date: 2013-10-11

Last Posted Date: 2014-04-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2

Registration Number: NCT01961128

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Early Changes In Multiparametric MRI In Prostate Cancer

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Device: MRI
Other: PSA Blood Test

First Posted Date: 2013-10-10

Last Posted Date: 2020-06-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT01959542

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

GSK1120212+GSK2141795 for Cervical Cancer

Phase 2

Terminated

Conditions: Cervical Cancer

Interventions: Drug: GSK1120212 (trametinib)
Drug: GSK2141795

First Posted Date: 2013-10-08

Last Posted Date: 2019-05-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 14

Registration Number: NCT01958112

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma

Not Applicable

Completed

Conditions: Monoclonal Gammopathy of Undetermined Significance
Smoldering Multiple Myeloma

Interventions: Behavioral: Relaxation Response Resiliency Program (3RP)

First Posted Date: 2013-10-07

Last Posted Date: 2017-03-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 93

Registration Number: NCT01955395

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

Phase 2

Completed

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Enzalutamide

First Posted Date: 2013-09-16

Last Posted Date: 2022-10-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 67

Registration Number: NCT01942837

Locations: 🇺🇸
South Shore Hospital, Weymouth, Massachusetts, United States
🇺🇸
University of Washington Medical Center/Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 2 locations

Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

Phase 1

Active, not recruiting

Conditions: Chronic GVHD
Complications of Organ Transplant Stem Cells
Chronic Graft Versus Host Disease

Interventions: Other: Treg-enriched infusion
Drug: Interleukin-2

First Posted Date: 2013-09-09

Last Posted Date: 2024-11-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT01937468

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Insitute, Boston, Massachusetts, United States

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

Phase 1

Completed

Conditions: Brain Metastases From HER2 and Breast Cancer
Advanced HER2-positive Breast Cancer

Interventions: Drug: ARRY-380 Twice Daily Dosage
Drug: ARRY-380 Once Daily
Drug: Trastuzumab

First Posted Date: 2013-08-13

Last Posted Date: 2024-11-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 41

Registration Number: NCT01921335

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Phase 2

Terminated

Conditions: Metastatic Breast Cancer
HER2-positive Breast Cancer

Interventions: Drug: Pertuzumab
Drug: Trastuzumab
Drug: eribulin

First Posted Date: 2013-07-31

Last Posted Date: 2018-12-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT01912963

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy

Early Phase 1

Completed

Conditions: Inflammatory Breast Carcinoma

Interventions: Drug: 89Zr-bevacizumab
Procedure: FDG-PET/CT
Procedure: MRI scan
Procedure: Tumor biopsies

First Posted Date: 2013-07-10

Last Posted Date: 2019-12-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2

Registration Number: NCT01894451

Locations: 🇺🇸
Brigham and Womens Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy